|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest-earning deposits | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Certificates of deposit in other banks | ||||||||||||||||||||
| Securities available for sale (“AFS”), at fair value | ||||||||||||||||||||
| Securities held to maturity (“HTM”), at amortized cost | ||||||||||||||||||||
| Other investments | ||||||||||||||||||||
| Loans held for sale | ||||||||||||||||||||
| Other assets held for sale | ||||||||||||||||||||
| Loans | ||||||||||||||||||||
| Allowance for credit losses - loans (“ACL-Loans”) | ||||||||||||||||||||
| Loans, net | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Bank owned life insurance (“BOLI”) | ||||||||||||||||||||
| Goodwill and other intangibles, net | ||||||||||||||||||||
| Accrued interest receivable and other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Stockholders’ Equity | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Noninterest-bearing demand deposits | ||||||||||||||||||||
| Interest-bearing deposits | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Short-term borrowings | ||||||||||||||||||||
| Long-term borrowings | ||||||||||||||||||||
| Other liabilities held for sale | ||||||||||||||||||||
| Accrued interest payable and other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ Equity: | ||||||||||||||||||||
| Common stock | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
| Preferred shares authorized (no par value) (in shares) | ||||||||||||||||||||
| Preferred shares issued (in shares) | ||||||||||||||||||||
| Preferred shares outstanding (in shares) | ||||||||||||||||||||
| Common shares authorized (par value $0.01 per share) (in shares) | ||||||||||||||||||||
| Common shares outstanding (in shares) | ||||||||||||||||||||
| Common shares issued (in shares) | ||||||||||||||||||||
Loading...
